Zai Lab reports sustained biomarker inhibition with ZL-1503 in Phase 1 trial
ZLAB•Zai Lab reported preliminary Phase 1/1b results for experimental atopic dermatitis treatment ZL-1503 in healthy volunteers, showing sustained inflammatory biomarker suppression with no serious adverse events or dose-limiting toxicities. The company expects repeated-dose results in patients in the first half of 2027.
1. Preliminary trial results
Zai Lab said ZL-1503 showed sustained suppression of inflammatory biomarkers in healthy volunteers in a Phase 1/1b trial, with no serious adverse events or dose-limiting toxicities reported. The drug’s extended half-life supports further evaluation of maintenance dosing once every 12 weeks.
2. Next updates
Results are scheduled to be presented at the American College of Allergy, Asthma & Immunology meeting on November 13, 2026. Repeated-dose results in patients with moderate-to-severe atopic dermatitis are expected in the first half of 2027.
